Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Current Assets (2020 - 2025)

Ovid Therapeutics' Current Assets history spans 6 years, with the latest figure at $74.4 million for Q4 2025.

  • For Q4 2025, Current Assets rose 32.94% year-over-year to $74.4 million; the TTM value through Dec 2025 reached $74.4 million, up 32.94%, while the annual FY2025 figure was $74.4 million, 32.94% up from the prior year.
  • Current Assets reached $74.4 million in Q4 2025 per OVID's latest filing, up from $28.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $236.7 million in Q1 2021 to a low of $28.8 million in Q3 2025.
  • Average Current Assets over 5 years is $117.8 million, with a median of $105.9 million recorded in 2023.
  • Peak YoY movement for Current Assets: soared 389.39% in 2021, then crashed 56.21% in 2025.
  • A 5-year view of Current Assets shows it stood at $190.5 million in 2021, then tumbled by 31.03% to $131.4 million in 2022, then fell by 16.58% to $109.6 million in 2023, then tumbled by 48.96% to $55.9 million in 2024, then surged by 32.94% to $74.4 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Current Assets are $74.4 million (Q4 2025), $28.8 million (Q3 2025), and $42.1 million (Q2 2025).